Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189420 | 0.85 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL1949588 | 0.84 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL17156171 | 0.77 | MAPT (0.55) | ALDH1A1SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL11784059 | 0.77 | MAPT (0.63) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL1949826 | 0.75 | MAPT (0.54) | ALDH1A1SMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL1121313 | 0.75 | ALDH1A1 (0.65) | ALDH1A1MAPTPOLBKDM4EFDPS | |
| SCHEMBL20529376 | 0.75 | ALDH1A3 (0.52) | ALDH1A1SMN1; SMN2MAPTPOLBFDPS | |
| SCHEMBL29958206 | 0.75 | ALDH1A1 (0.65) | ALDH1A1MAPTPOLBKDM4EFDPS | |
| SCHEMBL1950506 | 0.74 | MAPT (0.46) | ALDH1A1MAPTPOLBKDM4EESR1 | |
| SCHEMBL14784683 | 0.73 | MAPT (0.44) | ALDH1A1MAPTPOLBKDM4EESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136801-A1 | Novel Compounds | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136801-A1 | Novel Compounds | C1R, RB1, CNKSR1 | ALDH1A1 173/4885SMN1; SMN2 1340/4885MAPT 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.